Trial Profile

A Phase I trial of KROS 201 in patients with glioblastoma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KROS-201 (Primary)
Indications Glioblastoma
Focus Adverse reactions; First in man
Sponsors Kairos Pharma

Most Recent Events

14 Mar 2022 According to a Kairos pharma media release, the company has received FDA approval to proceed with this Phase 1 clinical trial in patients with recurrent glioblastoma, a type of brain cancer and will be conducted at Cedars Sinai Medical Center in Los Angeles.
22 Feb 2022 New trial record
15 Feb 2022 According to a Kairos pharma media release, this trial is anticipated to start in 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com